Literature DB >> 27642221

Uniformly Most Powerful Tests for Simultaneously Detecting a Treatment Effect in the Overall Population and at Least One Subpopulation.

Michael Rosenblum1.   

Abstract

We take the perspective of a researcher planning a randomized trial of a new treatment, where it is suspected that certain subpopulations may benefit more than others. These subpopulations could be defined by a risk factor or biomarker measured at baseline. We focus on situations where the overall population is partitioned into two, predefined subpopulations. When the true average treatment effect for the overall population is positive, it logically follows that it must be positive for at least one subpopulation. Our goal is to construct multiple testing procedures that maximize power for simultaneously rejecting the overall population null hypothesis and at least one subpopulation null hypothesis. We show that uniformly most powerful tests exist for this problem, in the case where outcomes are normally distributed. We construct new multiple testing procedures that, to the best of our knowledge, are the first to have this property. These procedures have the advantage of not requiring any sacrifice for detecting a treatment effect in the overall population, compared to the uniformly most powerful test of the overall population null hypothesis.

Entities:  

Keywords:  Familywise Type I error; Optimization; Personalized medicine

Year:  2014        PMID: 27642221      PMCID: PMC5026131          DOI: 10.1016/j.jspi.2014.07.001

Source DB:  PubMed          Journal:  J Stat Plan Inference        ISSN: 0378-3758            Impact factor:   1.111


  6 in total

1.  A method for testing a prespecified subgroup in clinical trials.

Authors:  Yang Song; George Y H Chi
Journal:  Stat Med       Date:  2007-08-30       Impact factor: 2.373

2.  A flexible strategy for testing subgroups and overall population.

Authors:  Mohamed Alosh; Mohammad F Huque
Journal:  Stat Med       Date:  2009-01-15       Impact factor: 2.373

3.  Optimal Tests of Treatment Effects for the Overall Population and Two Subpopulations in Randomized Trials, using Sparse Linear Programming.

Authors:  Michael Rosenblum; Han Liu; En-Hsu Yen
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

4.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

5.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

6.  Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.

Authors:  Irving Kirsch; Brett J Deacon; Tania B Huedo-Medina; Alan Scoboria; Thomas J Moore; Blair T Johnson
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.